Zobrazeno 1 - 10
of 18 669
pro vyhledávání: '"Angiotensin II receptor"'
Autor:
E. V. Rebrova, E. V. Shikh
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 20, Iss 5, Pp 506-513 (2024)
Aim. To study the pharmacodynamic parameters of the effectiveness of therapy with angiotensin II receptor blockers in the form of monotherapy and as part of combination drugs in patients with hypertension, depending on the genetic characteristics of
Externí odkaz:
https://doaj.org/article/446610ab1dd74ec6bf95ae1f8c150186
Autor:
Wen-Yu Lin, Jin-Lian Tsui, Hsiao-Wen Chiu, Wei-Ting Wong, Chun‑Hsien Wu, Hsien-Ta Hsu, Chen-Lung Ho, Shan-Pei Yeh, Yerra Koteswara Rao, Ann Chen, Chien-Chun Wang, Chung-Hua Hsu, Oleg V. Chernikov, Kuo-Feng Hua, Lan-Hui Li
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Background Gonorrhea, induced by Neisseria gonorrhoeae infection, stands as a prevalent sexually transmitted inflammatory disease globally. Our earlier research illuminated that N. gonorrhoeae-infected macrophages provoke inflammation by act
Externí odkaz:
https://doaj.org/article/ebd34357f8f3401aa2d43e4324d760d3
Publikováno v:
Current Issues in Molecular Biology, Vol 46, Iss 9, Pp 9760-9771 (2024)
Angiotensin II (AngII) receptor subtype 1 (AT1R) is involved in the pathogenesis of preeclampsia (PE). Angiotensin II receptor subtype 2 (AT2R) can antagonize the effects of AT1R, but its effects during pregnancy are not known. We investigated the ef
Externí odkaz:
https://doaj.org/article/b73c023db38b4cb2a0736901bd418131
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
The main goals of the pharmacological treatment of Heart failure with reduced ejection fraction (HFrEF) are the reduction of mortality and the prevention of hospitalizations. However, other outcomes such as improvements in cardiac remodeling and clin
Externí odkaz:
https://doaj.org/article/62625629354f45768f73e319bc5fd383
Publikováno v:
Transplantation Reports, Vol 9, Iss 3, Pp 100159- (2024)
Introduction: proteinuria is associated with poor allograft and patient survival in kidney transplant recipients (KTRs). This study aims to investigate the prevalence and risk factors of proteinuria in KTRs and its impact on kidney function during th
Externí odkaz:
https://doaj.org/article/be6c1ff2b2fa4712bd4b82c74f62bf96
Association of the protective effect of telmisartan on hearing loss among patients with hypertension
Autor:
Jung-Joon Cha, Yunjin Yum, Yong Hyun Kim, Eung Ju Kim, Yoon Chan Rah, Euyhyun Park, Gi Jung Im, Jae-Jun Song, Sung-Won Chae, June Choi, Hyung Joon Joo
Publikováno v:
Frontiers in Neurology, Vol 15 (2024)
AimHearing loss, affecting a significant portion of the global population, is prevented with peroxisome proliferator-activated receptor γ agonism. Understanding potential protective treatments is crucial for public health. We examine the effect of t
Externí odkaz:
https://doaj.org/article/8e37432b5fac419689f82b5e27539033
Publikováno v:
Data in Brief, Vol 55, Iss , Pp 110677- (2024)
This dataset demonstrates the use of computational fragmentation-based and machine learning-aided drug discovery to generate new lead molecules for the treatment of hypertension. Specifically, the focus is on agents targeting the renin-angiotensin-al
Externí odkaz:
https://doaj.org/article/8199e551724844618705745934773b73
Autor:
Ling Zhu, Guo-Cui Wei, Qing Xiao, Qian-Lan Chen, Qian Zhao, Xiu-xia Li, Ling-ai Pan, Xuan Xiong
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
BackgroundAngiotensin II receptor blockers (ARBs) are utilized for the management of hypertension and diabetes. Previous meta-analyses suggested that azilsartan medoxomil (AZL-M) improved blood pressure (BP) reduction, but there were no safety findin
Externí odkaz:
https://doaj.org/article/e2e9c9be0ece47bcb15813d28ba03848
Publikováno v:
Journal of Traditional and Complementary Medicine, Vol 14, Iss 2, Pp 215-222 (2024)
Angiotensin II receptor blockers (ARBs) are one of the standard treatments for diabetic kidney disease (DKD). Some patients may opt for Chinese herbal medicine (CHM) of their own free will. However, there is no real-world evidence regarding the effec
Externí odkaz:
https://doaj.org/article/59f34e30ecf5487fb67f738d55c591e8
Publikováno v:
BMC Musculoskeletal Disorders, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Background The therapeutic efficacy of renin-angiotensin system inhibitors (RASi) in elderly patients with hypertension and at risk of fractures has been in the limelight because of accumulating evidence that localized RAS activation in bone
Externí odkaz:
https://doaj.org/article/10990194f346433d862c6d33a1dee7f8